Gut Microbiota and Metabolome Changes in Three Pulmonary Hypertension Rat Models

Author:

Luo Lingjie12,Yin Haoyang1,Gou Deming1

Affiliation:

1. Shenzhen Key Laboratory of Microbial Genetic Engineering, Vascular Disease Research Center, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen 518060, China

2. School of Pharmaceutical Sciences, Shenzhen University Health Science Center, Shenzhen University, Shenzhen 518060, China

Abstract

Dysbiosis of the gut microbiota and metabolites is found in both pulmonary hypertension patients and pulmonary hypertension rodent models. However, the exact changes in gut microbiota during the development of pulmonary hypertension is unclear. The function of the gut microbiota is also ambiguous. Here, this study showed that the gut microbiota was disrupted in rats with hypoxia (Hyp)-, hypoxia/Sugen5416 (HySu)-, and monocrotaline (MCT)-induced pulmonary hypertension. The gut microbiota is dynamically changed during the development of Hyp-, HySu-, and MCT-induced rat pulmonary hypertension. The variation in the α diversity of the gut microbiota in Hyp-induced pulmonary hypertension rats was similar to that in rats with MCT-induced pulmonary hypertension and different from that in rats with HySu-induced pulmonary hypertension. In addition, six plasma biomarkers, His, Ala, Ser, ADMA, 2-hydroxybutyric acid, and cystathionine, were identified in Hyp-induced pulmonary hypertension rats. Furthermore, a disease-associated network connecting Streptococcus with Hyp-induced pulmonary hypertension-associated metabolites was described here, including trimethylamine N-oxide, Asp, Asn, Lys, His, Ser, Pro, and Ile.

Funder

Shenzhen-Hong Kong Collaborative Innovation Research

National Natural Science Foundation of China

Shenzhen Municipal Basic Research Program Grant

Guangdong Provincial Key Laboratory of Regional Immunity and Diseases

Publisher

MDPI AG

Subject

Virology,Microbiology (medical),Microbiology

Reference44 articles.

1. Macitentan and morbidity and mortality in pulmonary arterial hypertension;Pulido;N. Engl. J. Med.,2013

2. The prostacyclin pathway in pulmonary arterial hypertension: A clinical review;Expert Rev. Respir. Med.,2017

3. Endothelin receptor antagonists for pulmonary arterial hypertension;Liu;Cochrane Database Syst. Rev.,2009

4. Phosphodiesterase 5 inhibitors for pulmonary hypertension;Barnes;Cochrane Database Syst. Rev.,2019

5. Treatment of pediatric pulmonary arterial hypertension: A focus on the NO-sGC-cGMP pathway;Beghetti;Pediatr. Pulmonol.,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3